MDxHealth SA (MDXH) vs Exagen (XGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Exagen (XGN) has outperformed MDxHealth SA (MDXH) over the past year, losing 25.6% versus a loss of 87.2%. Exagen is the larger company by market cap ($201.1 million vs $55.3 million), about 3.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDXH | XGN |
|---|---|---|
| Share price | $0.5798 | $8.30 |
| Market cap | $55.32M | $201.07M |
| 1-day change | -0.12% | +1.59% |
| YTD return | -83.74% | +34.38% |
| 1-year return | -87.16% | -25.59% |
| 5-year return | — | -35.31% |
| EPS (TTM) | $-0.70 | $-0.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.33 | $12.23 |
| 52-week low | $0.40 | $2.59 |
| Distance from 52-week high | -89.12% | -32.13% |
| Analyst consensus | none | none |
| Avg. price target upside | +210.45% | +22.17% |
| Average volume | 5.69M | 331.27K |
| Shares outstanding | 95.42M | 24.23M |
| Employees | 364 | 216 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Exagen is about 3.6 times larger than MDxHealth SA by market value ($201.07M vs $55.32M).
- XGN has outperformed MDXH by 61.6 percentage points over the past year.
About MDxHealth SA
MDXH stock →MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Health Care · Medical Specialities · 364 employees
About Exagen
XGN stock →Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States.
Health Care · Medical Specialities · 216 employees
MDXH vs XGN FAQ
Which is bigger, MDxHealth SA or Exagen?
Exagen (XGN) is larger, with a market capitalization of $201.07M compared with $55.32M for MDxHealth SA (MDXH).
Which stock has performed better over the past year, MDXH or XGN?
XGN returned -25.59% over the past 12 months, compared with -87.16% for MDXH (price return, excluding dividends). Past performance does not predict future results.
Are MDxHealth SA and Exagen in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.